liver fibrosis – Medxy AI

Enhancing Prognostication in Chronic Liver Disease: The Role of Liver Corrected T1 and Magnetic Resonance Elastography in Real-World Clinical Practice

By MedXY 10/29/2025

This study highlights the complementary utility of liver corrected T1 (cT1) and magnetic resonance elastography (MRE) for predicting chronic liver disease progression, emphasizing the critical prognostic role of disease activity beyond fibrosis severity, especially in steatotic liver disease.

Gastroenterology news

Targeting Claudin-1: A Novel Therapeutic Approach for Primary Sclerosing Cholangitis

By MedXY 10/28/2025

Claudin-1 is upregulated in primary sclerosing cholangitis (PSC), promoting biliary fibrosis and cholestasis. Preclinical models show that Claudin-1-specific monoclonal antibodies reduce liver injury and fibrosis, highlighting a promising therapeutic target for PSC.

Cardiology Gastroenterology news

Hypertension as a Key Driver of Liver Fibrosis Progression and Adverse Outcomes in MASLD: Evidence from Large Cohorts

By MedXY 10/28/2025

Hypertension independently worsens clinical outcomes and liver fibrosis progression in MASLD, highlighting the need for integrated cardiovascular and hepatic care.

Gastroenterology Internal Medicine news

Bexotegrast in Primary Sclerosing Cholangitis: Promising Safety and Pharmacodynamics from Phase II INTEGRIS-PSC Trial

By MedXY 10/28/2025

The Phase II INTEGRIS-PSC trial demonstrates that bexotegrast, a dual αvβ6/αvβ1 integrin inhibitor, is well tolerated in PSC patients with liver fibrosis and shows potential to attenuate fibrotic progression, supporting integrin-targeted therapy as a novel approach.

Diabetes & Endocrinology Gastroenterology news

Noninvasive Biomarkers Track Semaglutide Efficacy in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 10/09/2025

A phase 2b trial demonstrates that several noninvasive tests reliably reflect treatment response to semaglutide in patients with metabolic dysfunction-associated steatohepatitis, correlating with histologic improvements over 72 weeks.

Diabetes & Endocrinology Gastroenterology Specialties

Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial

By MedXY 08/27/2025

The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

Intermittent Fasting vs Low-Calorie Diet in Managing Metabolic-Associated Fatty Liver Disease: Comparative Effects on Inflammation, Lipids, Glycemic Control, and Liver Fibrosis

By MedXY 08/26/2025

This RCT compares 16:8 intermittent fasting and low-calorie diets in MAFLD patients, revealing both improve liver enzymes and anthropometrics, but low-calorie diet shows superior reduction in liver steatosis, fibrosis, and triglycerides.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies

By MedXY 08/24/2025

HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.

Clinical Updates Gastroenterology news Specialties

Two-Step Clinical Pathway for MASLD: Precision Risk Stratification of Hepatic Events Validated in a Multinational Prospective Cohort

By MedXY 08/01/2025

A large, multinational cohort study demonstrates that a two-step algorithm—combining FIB-4 with VCTE—precisely stratifies MASLD patients by liver-related event risk, optimizing resource use and guiding clinical management.

Gastroenterology Medical News news Specialties

Sharp Rise in Advanced Alcohol-Related Liver Disease Despite Stable Drinking Rates: Changing Population Risks Highlighted by US Data

By MedXY 07/31/2025

A twofold rise in advanced liver fibrosis among US heavy drinkers over two decades is linked to increased metabolic syndrome, age, and socioeconomic risk, not higher alcohol intake.